Retatrutide Development Pipeline Phase 3 trials currently underway will generate the comprehensive data package required for FDA approval
Product Information Compound Name CJC 1295 (No DAC) and Ipamorelin Net Content 10 mg total peptide content Composition CJC 1295 (No DAC) 5 mg Ipamorelin 5 mg Purity Greater than 99 percent (HPLC verified) Form Lyophilized peptide blend Storage Store unreconstituted material at ?20C for long term stability
Who Qualifies for GLP-1 Medication Without Obesity Diagnosis Individuals with prediabetes, type 2 diabetes, or cardiovascular risk factors may be appropriate candidates for GLP-1 therapy regardless of BMI
Danishs clinical perspective will help put these findings into context for parents seeking hope and effective integrative care
TRIUMPH-1 (NCT05929066), the Phase 3 registration trial for the obesity indication, reported topline results on May 21, 2026 : average weight loss of 28.3% at 80 weeks at the highest dose in 2,339 participants, versus 2.2% on placebo, and 30.3% at 104 weeks among participants with a BMI of 35 or above who continued in a pre-specified extension
